Lytix Biopharma AS (OSL:LYTIX)

Lytix Biopharma AS Income Statement

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	-	11.13	3.99	11.03	19.31
Revenue	-	11.13	3.99	11.03	19.31
Revenue Growth (YoY)	-	178.98%	-63.82%	-42.86%	373.91%
Gross Profit	-	11.13	3.99	11.03	19.31
Selling, General & Admin	32.62	22.63	24.37	20.41	31.1
Research & Development	13.8	72.57	63.17	45.61	23.74
Other Operating Expenses	16.6	10.92	12.28	9.76	12.01
Operating Expenses	64.03	107.03	100.78	76.7	67.29
Operating Income	-64.03	-95.9	-96.79	-65.67	-47.99
Interest Expense	-0.21	-0.13	-0.06	-0.15	-0.07
Interest & Investment Income	2.33	1.51	2.35	1.41	0.14
Currency Exchange Gain (Loss)	0.17	-0.08	4.01	7.72	-0.17
Other Non Operating Income (Expenses)	1.76	0.33	2.59	0.61	0.01
EBT Excluding Unusual Items	-59.98	-94.27	-87.9	-56.07	-48.08
Pretax Income	-59.98	-94.27	-87.9	-56.07	-48.08
Earnings From Continuing Operations	-59.98	-94.27	-87.9	-56.07	-48.08
Net Income	-59.98	-94.27	-87.9	-56.07	-48.08
Net Income to Common	-59.98	-94.27	-87.9	-56.07	-48.08
Shares Outstanding (Basic)	68	54	40	40	33
Shares Outstanding (Diluted)	68	54	40	40	33
Shares Change (YoY)	26.05%	35.05%	1.01%	19.50%	26.57%
EPS (Basic)	-0.88	-1.74	-2.19	-1.41	-1.45
EPS (Diluted)	-0.88	-1.74	-2.19	-1.41	-1.45
Free Cash Flow	-59.85	-70.37	-96.02	-52.78	-44.61
Free Cash Flow Per Share	-0.88	-1.30	-2.40	-1.33	-1.34
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-861.29%	-2425.08%	-595.28%	-248.54%
Profit Margin	-	-846.64%	-2202.38%	-508.29%	-249.02%
Free Cash Flow Margin	-	-632.05%	-2405.86%	-478.47%	-231.04%
EBITDA	-63.99	-95.83	-96.72	-65.64	-47.53
EBITDA Margin	-	-	-	-	-246.20%
D&A For EBITDA	0.04	0.07	0.06	0.03	0.45
EBIT	-64.03	-95.9	-96.79	-65.67	-47.99
EBIT Margin	-	-	-	-	-248.54%
Revenue as Reported	-	11.13	3.99	11.03	19.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.